TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11952431

Group type: EXPERIMENTAL
Intervention: Remifentanil (R) administered in incremental dosages (0.1-0.25-0.5 microg/kg/min)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Remifentanil (R)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fentanyl (F) 1.5 microg/kg and midazolam (M) titrated between 1 and 10 mg
Number of subjects: 74
Study: 9467551

Group type: EXPERIMENTAL
Intervention: Threshold dose plus 1/2 ampoule of FSH
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 1 ampoule above the threshold dose of FSH
Number of subjects: 23

Group type: COMPARATOR
Intervention: Threshold dose of FSH
Number of subjects: 23

Group type: COMPARATOR
Intervention: FSH level increase above the threshold
Number of subjects: 23
Study: 8699040

Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional intravenous infusion of oxytocin
Number of subjects: 96
Study: 2550167

Group type: EXPERIMENTAL
Intervention: Nadolol (240 mg per day, increased weekly for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg per day, increased weekly for 4 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6457170

Group type: EXPERIMENTAL
Intervention: 6059-S
Number of subjects: 16

Group type: COMPARATOR
Intervention: ABPC (2 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SBPC
Number of subjects: 16
Study: 30935548

Group type: EXPERIMENTAL
Intervention: Purslane cream (2% w/w)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lanolin ointment
Number of subjects: 86
Study: 28734858

Group type: EXPERIMENTAL
Intervention: 5-grass pollen tablet
Number of subjects: 2512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2512
Study: 26098833

Group type: EXPERIMENTAL
Intervention: Jinlida (9 g) TID for 12 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo TID for 12 weeks
Number of subjects: 186
Study: 24846373

Group type: EXPERIMENTAL
Intervention: Integrated diagnostics (ID) algorithm
Number of subjects: 1224
Study: 22417212

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei ssp. paracasei F19 (LF19) 10^8 colony forming units per serving
Number of subjects: 179

Group type: COMPARATOR
Intervention: Cereals without LF19 (placebo)
Number of subjects: 179
Study: 20391059

Group type: EXPERIMENTAL
Intervention: SWF Intervention
Number of subjects: 806

Group type: COMPARATOR
Intervention: NIDA Standard Intervention
Number of subjects: 806
Study: 18416983

Group type: EXPERIMENTAL
Intervention: Silicone tubes used after primary EN‐DCR
Number of subjects: 42

Group type: COMPARATOR
Intervention: No silicone tubes used after primary EN‐DCR
Number of subjects: 42
Study: 15756155

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 36
Study: 12175135

Group type: EXPERIMENTAL
Intervention: MEDLINE search methodologies
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Yearly publication rate
Number of subjects: 602
Study: 10438255

Group type: EXPERIMENTAL
Intervention: Leprosy patients in reversal reaction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (healthy Ethiopians)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Leprosy patients not in reversal reaction
Number of subjects: 24
Study: 7752258

Group type: EXPERIMENTAL
Intervention: Oral calcium carbonate (CaCO3) supplements (1.5 g) three times a day for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (cellulose and starch) three times a day for 12 weeks
Number of subjects: 30
Study: 1703920

Group type: EXPERIMENTAL
Intervention: Nitroglycerin tape (5 mg) and ibopamine (100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nitroglycerin tape (5 mg) and nifedipine (10 mg)
Number of subjects: 15
Study: 6958484

Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (100 micrograms daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31745073

Group type: EXPERIMENTAL
Intervention: Self-reported alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotype at rs1229984
Number of subjects: 0
Study: 28671332

Group type: EXPERIMENTAL
Intervention: Betaine intervention
Number of subjects: 0
Study: 25702819

Group type: EXPERIMENTAL
Intervention: CYP2B6*6/*6 genotype
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CYP2B6*1/*6 genotype
Number of subjects: 49

Group type: COMPARATOR
Intervention: CYP2B6*1/*1 genotype
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CYP2B6*6 genotype
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CYP2B6*6 genotype and age
Number of subjects: 49
Study: 23419134

Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg orally daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg orally daily + Prednisone 10 mg daily
Number of subjects: 59
Study: 21953407

Group type: EXPERIMENTAL
Intervention: NP/CHW intervention (n=261)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) (n=264)
Number of subjects: 525
Study: 19728196

Group type: EXPERIMENTAL
Intervention: MDI + spacer
Number of subjects: 303

Group type: COMPARATOR
Intervention: MDI alone
Number of subjects: 303
Study: 17942470

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 4 months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline for 4 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo for 4 months
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 15477504

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment (2-g/kg loading dose, boosters of 0.4 g/kg every 6 weeks for 1 year)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) treatment
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 11825312

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibitors of platelet aggregation (including nitric oxide from L-arginine or glyceryl trinitrate) and anticoagulants (low molecular weight heparin, defibrotide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous infusions of prostaglandins (PGs) PGE1 and PGI2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine and basic fibroblast growth factor (bFGF)
Number of subjects: 0
Study: 9884849

Group type: EXPERIMENTAL
Intervention: Accelographic post‐tetanic count at the great toe
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mechanical post‐tetanic count at the great toe
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Accelographic train‐of‐four ratios at the great toe
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mechanical train‐of‐four ratios at the great toe
Number of subjects: 24
Study: 8172381

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN) applied every eight hours until disappearance of inflammation signs.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo ointment applied every eight hours until disappearance of inflammation signs.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 21
Study: 3278754

Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13-CRA, 100 mg/m2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (13-CRA and placebo)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid (13-CRA)
Number of subjects: 68
Study: 31925721

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Duloxetine (60 mg daily)
Number of subjects: 82
Study: 30128934

Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma (LP-PRP) injection
Number of subjects: 98

Group type: COMPARATOR
Intervention: Hyaluronic acid injection
Number of subjects: 98

Group type: COMPARATOR
Intervention: NSAID treatment
Number of subjects: 98
Study: 28536030

Group type: EXPERIMENTAL
Intervention: Hib-TT
Number of subjects: 4009

Group type: COMPARATOR
Intervention: Hib-TT control
Number of subjects: 4009

Group type: COMPARATOR
Intervention: Combination Hib-TT vaccine
Number of subjects: 4009
Study: 26301756

Group type: EXPERIMENTAL
Intervention: Computerised-CBT (C-CBT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Waiting List
Number of subjects: 112
Study: 23996468

Group type: EXPERIMENTAL
Intervention: AFI-NBI
Number of subjects: 64

Group type: COMPARATOR
Intervention: WLE
Number of subjects: 64
Study: 21916529

Group type: EXPERIMENTAL
Intervention: FT (FlexTouch*)
Number of subjects: 160
Study: 18845963

Group type: EXPERIMENTAL
Intervention: 6-day accelerometry
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Self-report
Number of subjects: 951
Study: 16023065

Group type: EXPERIMENTAL
Intervention: Technolas 217A
Number of subjects: 30

Group type: COMPARATOR
Intervention: VISX S3
Number of subjects: 30
Study: 12219853

Group type: EXPERIMENTAL
Intervention: Behavior-identification task with situational constraints (easy task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior-identification task with situational constraints (difficult task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispositional-inference task (easy task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispositional-inference task (difficult task)
Number of subjects: 0
Study: 10334399

Group type: EXPERIMENTAL
Intervention: Judgment of Line Orientation Test
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Facial Recognition Test
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Judgment of Line Orientation Test and Facial Recognition Test
Number of subjects: 32
Study: 9101886

Group type: EXPERIMENTAL
Intervention: Piggy-back OLT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard OLT
Number of subjects: 31
Study: 1919317

Group type: EXPERIMENTAL
Intervention: Adrenaline 1:80,000
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 7118100

Group type: EXPERIMENTAL
Intervention: Fulltime comprehensive rehabilitation program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Part-time supportive treatment program
Number of subjects: 102
Study: 30399035

Group type: EXPERIMENTAL
Intervention: Lay worker administered combination intervention (individualized health education, retention/adherence support, appointment reminders, missed visit tracking)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Both intervention and SOC
Number of subjects: 340
Study: 30463598

Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise programme consisting of 30 min HIIT (30 s 100% peak power output/30 s passive recovery) on the arm crank ergometer and 15 min of upper body circuit resistance training, 2 sessions per week.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 12-week supervised exercise programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: usual care (medical treatment)
Number of subjects: 30
Study: 27067306

Group type: EXPERIMENTAL
Intervention: Sun protection intervention
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Sunscreen use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Lip balm use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Wide-brimmed hats use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Sleeved shirts use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Pants use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Sunglasses use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Shade use
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Limiting time outdoors
Number of subjects: 340
Study: 24467336

Group type: EXPERIMENTAL
Intervention: Therapeutic assessment (TA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Structured goal‐focused pretreatment intervention (GFPTI)
Number of subjects: 74
Study: 21749169

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 7.5% povidone‐iodine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 20232572

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17047171

Group type: EXPERIMENTAL
Intervention: hGH (0.1 mg/kg/d for 3 weeks, then 0.1 mg/kg 3 days a week for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (subcutaneous saline)
Number of subjects: 0
Study: 14609147

Group type: EXPERIMENTAL
Intervention: AAS administration with resistance training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (resistance trained)
Number of subjects: 32
Study: 11029341

Group type: EXPERIMENTAL
Intervention: NPPV + ET
Number of subjects: 45

Group type: COMPARATOR
Intervention: ET
Number of subjects: 45
Study: 8979662

Group type: EXPERIMENTAL
Intervention: 1% hydroxyamphetamine plus 0.25% tropicamide (Paremyd)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% tropicamide combined with 2.5% phenylephrine (TP)
Number of subjects: 60
Study: 1426384

Group type: EXPERIMENTAL
Intervention: Biopsied group (embryo biopsy on day 2 after insemination)
Number of subjects: 129
Study: 3998786

Group type: EXPERIMENTAL
Intervention: Blood transfusions during definitive surgical therapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: No blood transfusions during definitive surgical therapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Blood transfusions in patients receiving chemotherapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Blood transfusions in patients with large tumors (greater than 150 mL)
Number of subjects: 156
Study: 31059282

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G4® or G5®
Number of subjects: 17

Group type: COMPARATOR
Intervention: Self-Monitoring of Blood Glucose (SMBG) using OmniPod® Personal Diabetes Manager
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 17
Study: 30409765

Group type: EXPERIMENTAL
Intervention: Facebook advertising for recruitment
Number of subjects: 1145
Study: 26968881

Group type: EXPERIMENTAL
Intervention: Metronidazole (400 mg) plus penicillin (1,000,000 IU) for 10 days and 7 days respectively
Number of subjects: 200

Group type: COMPARATOR
Intervention: Penicillin (1,000,000 IU) alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Metronidazole plus penicillin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Penicillin alone
Number of subjects: 200
Study: 25362813

Group type: EXPERIMENTAL
Intervention: Imatynib-Biofarm 100 mg film-coated tablet (test)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Imatynib-Biofarm 400 mg film-coated tablet (test)
Number of subjects: 85
Study: 22445084

Group type: EXPERIMENTAL
Intervention: Mailed prenotification letter
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Faxed prenotification letter
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Questionnaires sealed with a label marked attention to doctor
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Questionnaires sealed with a control label
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: More personalized approach at final reminder
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Less personalized approach at final reminder
Number of subjects: 1000
Study: 20200284

Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Provider education only (PROV)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 119
Study: 18028245

Group type: EXPERIMENTAL
Intervention: Lupin challenge in peanut-allergic children (N=9)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Lupin challenge in atopic controls (N=46)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Sensitization to lupin in peanut-allergic children
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sensitization to lupin in atopic controls
Number of subjects: 93
Study: 27946605

Group type: EXPERIMENTAL
Intervention: RT plus amifostine (RT+AF)
Number of subjects: 49

Group type: COMPARATOR
Intervention: RT only
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: RT+AF
Number of subjects: 49
Study: 12021830

Group type: EXPERIMENTAL
Intervention: 12 g oral glucose tablets
Number of subjects: 41

Group type: COMPARATOR
Intervention: Matched placebo tablets
Number of subjects: 41
Study: 10423646

Group type: EXPERIMENTAL
Intervention: 4 tablets of potassium-magnesium citrate per day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 7 tablets of potassium-magnesium citrate per day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 10 tablets of potassium-magnesium citrate per day
Number of subjects: 61
Study: 9001445

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Handgrip test (HT)
Number of subjects: 10
Study: 2391183

Group type: EXPERIMENTAL
Intervention: 70 degrees C thermoplasticized gutta-percha with sealer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70 degrees C thermoplasticized gutta-percha without sealer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 0
Study: 6271386

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide alone
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hexa-CAF regimen (hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Hexa-CAF regimen
Number of subjects: 57
Study: 30949233

Group type: EXPERIMENTAL
Intervention: RG method integrated in Flexible Assertive Community Treatment (FACT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard FACT
Number of subjects: 180
Study: 26259551

Group type: EXPERIMENTAL
Intervention: Visual (VIS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verbal (VER)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 90
Study: 25398581

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Olanzapine 5 mg
Number of subjects: 150
Study: 24004959

Group type: EXPERIMENTAL
Intervention: Tocopheryl acetate 20% spray
Number of subjects: 45

Group type: COMPARATOR
Intervention: Permethrin 1% creme rinse
Number of subjects: 45
Study: 21410418

Group type: EXPERIMENTAL
Intervention: HOPE (Helping Other Partners Excel) intervention package
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 62
Study: 19597921

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 16733299

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 137
Study: 14646190

Group type: EXPERIMENTAL
Intervention: TACC-supplemented tea (1.1 mg thiamin, 1240 mg arginine, 52 mg caffeine, 540 mg citric acid); n=16
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control tea; n=15
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TACC-supplemented tea
Number of subjects: 31
Study: 11041441

Group type: EXPERIMENTAL
Intervention: Stuartnatal Plus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 30
Study: 9377121

Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy
Number of subjects: 100
Study: 8096549

Group type: EXPERIMENTAL
Intervention: Denopamine 40 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Denopamine
Number of subjects: 10
Study: 3517554

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (80 mg by mouth)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29486807

Group type: EXPERIMENTAL
Intervention: MBCT + TAU
Number of subjects: 120

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study: 29532075

Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/d of protein plus testosterone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/d of protein plus placebo
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.8 g/kg/d of protein plus testosterone
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.8 g/kg/d of protein plus placebo
Number of subjects: 92
Study: 27216371

Group type: EXPERIMENTAL
Intervention: Offline communication with unfamiliar conversation partners
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Online communication with unfamiliar conversation partners
Number of subjects: 76

Group type: COMPARATOR
Intervention: Offline communication with familiar conversation partners
Number of subjects: 76

Group type: COMPARATOR
Intervention: Online communication with familiar conversation partners
Number of subjects: 76
Study: 24704645

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 21855173

Group type: EXPERIMENTAL
Intervention: E2 (estradiol patch)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: E2+CORT (estradiol patch/hydrocortisone)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CORT (hydrocortisone)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 20973322

Group type: EXPERIMENTAL
Intervention: 0.0125% capsaicin gel applied three times daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gel applied three times daily for 4 weeks
Number of subjects: 100